Cash on Hand for Boston Scientific (BSX)
According to Boston Scientific's latest reported financial statements, the company's latest reported cash and short-term investments is $2.04B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingCash on HandSwitch metric
Latest period
$2.04B
YoY change
+394.0%
5Y CAGR
+3.4%
Peak year (2025)
$2.04B
Latest annual
$2.04B
Cash on Hand history chart for Boston Scientific (BSX) from 1991 to 2025
Cash on Hand history table for Boston Scientific (BSX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $2.04B | +394.0% | ||
| 2024 | $414.00M | -52.1% | ||
| 2023 | $865.00M | -6.8% | ||
| 2022 | $928.00M | -51.8% | ||
| 2021 | $1.93B | +11.0% | ||
| 2020 | $1.73B | +699.1% | ||
| 2019 | $217.00M | +48.6% | ||
| 2018 | $146.00M | -22.3% | ||
| 2017 | $188.00M | -4.1% | ||
| 2016 | $196.00M | -38.6% | ||
| 2015 | $319.00M | -45.7% | ||
| 2014 | $587.00M | +170.5% | ||
| 2013 | $217.00M | +4.8% | ||
| 2012 | $207.00M | -22.5% | ||
| 2011 | $267.00M | +25.4% | ||
| 2010 | $213.00M | -75.3% | ||
| 2009 | $864.00M | -47.3% | ||
| 2008 | $1.64B | +13.0% | ||
| 2007 | $1.45B | -12.9% | ||
| 2006 | $1.67B | +96.7% | ||
| 2005 | $848.00M | -48.3% | ||
| 2004 | $1.64B | +144.4% | ||
| 2003 | $671.00M | +142.2% | ||
| 2002 | $277.00M | +49.7% | ||
| 2001 | $185.00M | +208.3% | ||
| 2000 | $60.00M | -23.1% | ||
| 1999 | $78.00M | +11.0% | ||
| 1998 | $70.30M | +21.2% | ||
| 1997 | $58.00M | -0.9% | ||
| 1996 | $58.50M | -49.1% | ||
| 1995 | $115.00M | +27.6% | ||
| 1994 | $90.10M | +48.2% | ||
| 1993 | $60.80M | -36.3% | ||
| 1992 | $95.40M | +1516.9% | ||
| 1991 | $5.90M | — |
Cash on Hand values are taken from Boston Scientific's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Boston Scientific (BSX) reported cash and short-term investments of $2.04B – surged 394.0% year-over-year.
Over 2020–2025 (5 years), Boston Scientific cash and short-term investments expanded at a +3.4% compound annual rate, with the latest reading among the more recent periods of the dataset.
Across the available history, cash and short-term investments reached its high of $2.04B in 2025 and its low of $5.90M in 1991.
Within Healthcare, Boston Scientific (BSX) ranks 9th among 8 peers we track. The peer median for cash and short-term investments is $11.85B.
Boston Scientific Cash on Hand by Year
Boston Scientific Cash on Hand 2025: $2.04B
Boston Scientific cash and short-term investments in 2025 was $2.04B, surged 394.0% from 2024. This figure represents the highest annual value in the available history.
Boston Scientific Cash on Hand 2024: $414.00M
Boston Scientific cash and short-term investments in 2024 was $414.00M, plunged 52.1% below 2023.
Boston Scientific Cash on Hand 2023: $865.00M
Boston Scientific cash and short-term investments in 2023 was $865.00M, declined 6.8% below 2022.
Boston Scientific Cash on Hand 2022: $928.00M
Boston Scientific cash and short-term investments in 2022 was $928.00M, plunged 51.8% below 2021.
Boston Scientific Cash on Hand 2021: $1.93B
Boston Scientific cash and short-term investments in 2021 was $1.93B.
See more financial history for Boston Scientific (BSX).
Sector peers — Cash on Hand
Companies in the same sector as Boston Scientific, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Boston Scientific's cash and short-term investments?
- Latest reported cash and short-term investments for Boston Scientific (BSX) is $2.04B (period ending December 31, 2025).
How has Boston Scientific cash and short-term investments changed year-over-year?
- Boston Scientific (BSX) cash and short-term investments changed +394.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Boston Scientific cash and short-term investments?
- Boston Scientific (BSX) cash and short-term investments compound annual growth rate is +3.4% over the most recent 5 years available.
When did Boston Scientific cash and short-term investments hit its highest annual value?
- Boston Scientific cash and short-term investments reached its highest annual value of $2.04B in 2025.
What was Boston Scientific cash and short-term investments in 2024?
- Boston Scientific (BSX) cash and short-term investments in 2024 was $414.00M.
What was Boston Scientific cash and short-term investments in 2025?
- Boston Scientific (BSX) cash and short-term investments in 2025 was $2.04B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BSX Overview
Company profile, financial tools, and key metrics
BSX Revenue Counter
Earns $653.70 every second. See per minute, hour, and day.
BSX Earnings Counter
Earns $112.66 per second net profit. See per minute, hour, and day.
BSX Economic Scale
Exceeds Niger's GDP. Compare with world economies.
BSX What If Invested
What if you had invested $1,000? See historical returns from any date.
BSX How It Makes Money
Discover visual breakdown of $20.61B in revenue — where it comes from and where it goes.
BSX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BSX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BSX Daily Price Character
Balanced · 48.8% historical win rate (green days). Streaks & record days.
BSX Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BSX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.